Sugi Predict

Sugi Predict / Compounds / SCHEMBL7200997

SCHEMBL7200997

SCHEMBL7200997

COC(CCC(=O)O)(CCC(=O)O)C(=O)c1cccc2cc3cccc(C(=O)C(CCC(=O)O)(CCC(=O)O)OC)c3cc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLA2G2D Q9UNK4 1/20 0.38
▸ KDM4E B2RXH2 4/20 0.38
▸ ALDH1A1 P00352 4/20 0.38
▸ GAA P10253 1/20 0.38
▸ HPGD P15428 3/20 0.37
▸ HSD17B10 Q99714 3/20 0.37
▸ MTNR1A P48039 2/20 0.35
▸ CDC25B P30305 4/20 0.34
▸ KMT2A Q03164 3/20 0.34
▸ MEN1 O00255 2/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ GLA P06280 2/20 0.34
▸ PTPN1 P18031 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CNR2 P34972 1/20 0.33
▸ GABRA1 P14867 1/20 0.32
▸ GABRB2 P47870 1/20 0.32
▸ FFAR1 O14842 2/20 0.32
▸ AKR1B1 P15121 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7196641 0.80 KDM4E (0.41) PLA2G2DKDM4EALDH1A1GAAHPGD
SCHEMBL7201864 0.73 CES1 (0.50) ALDH1A1GAAKMT2APOLBNR4A2
SCHEMBL7199163 0.70 KDM4E (0.38) PLA2G2DKDM4EALDH1A1GAAHPGD
SCHEMBL6761980 0.68 ALDH1A1 (0.54) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL29403597 0.68 ALDH1A1 (0.54) KDM4EALDH1A1GAAHPGDHSD17B10
Bromide SCHEMBL11589064 0.67 KDM4E (0.46) PLA2G2DKDM4EALDH1A1GAAHPGD
SCHEMBL30367135 0.67 PTPN1 (0.66) PLA2G2DKDM4EALDH1A1GAAHPGD
SCHEMBL71261 0.67 PTPN1 (0.66) PLA2G2DKDM4EALDH1A1GAAHPGD
SCHEMBL9984575 0.66 PTPN1 (0.51) KDM4EALDH1A1GAAHPGDHSD17B10
SCHEMBL28438120 0.65 KDM4E (0.61) PLA2G2DKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610663-B2 Antisense compound with targeting and RNA cleaving moieties, preferably an imidazole functionality conjugated to the targeting oligonucleotide via linkers ISIS PHARMACEUTICALS, INC. 2003-08-26 — — US disclosed
US-20020160972-A1 Compositions and methods for modulating RNA ISIS PHARMACEUTICALS, INC. 2002-10-31 — — US disclosed
US-6358931-B1 OLIGONUCLETIDE CONJUGATED TO IMIDAZOLE; INTERCALATION AND COORDINATION COMPOUNDS; MEDICAL DIAGNOSIS, GENE THERAPY; ANTISENSE AGENTS ISIS PHARMACEUTICALS, INC. 2002-03-19 — — US disclosed
EP-0656790-A1 COMPOSITIONS AND METHODS FOR MODULATING RNA ISIS PHARMACEUTICALS, INC. (US) 1995-06-14 — — EP disclosed
WO-1993017717-A1 COMPOSITIONS AND METHODS FOR MODULATING RNA ISIS PHARMACEUTICALS, INC. (US) 1993-09-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020160972-A1 Compositions and methods for modulating RNA RNGTT, NSUN3, NSUN2 PLA2G2D 2420/4885KDM4E 2315/4885ALDH1A1 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.